Donatus U Ekwueme1, Benjamin T Allaire2, Gery P Guy3, Sarah Arnold2, Justin G Trogdon4. 1. Division of Cancer Prevention and Control, CDC, Atlanta, Georgia. Electronic address: dce3@cdc.gov. 2. RTI International, Research Triangle Park, North Carolina; 3. Division of Cancer Prevention and Control, CDC, Atlanta, Georgia. 4. Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
INTRODUCTION: A few studies have examined the costs of breast cancer treatment in a Medicaid population at the state level. However, no study has estimated medical costs for breast cancer treatment at the national level for women aged 19-44 years enrolled in Medicaid. METHODS: A sample of 5,542 younger women aged 19-44 years enrolled in fee-for-service Medicaid with diagnosis codes for breast cancer in 2007 were compared with 4.3 million women aged 19-44 years enrolled in fee-for-service Medicaid without breast cancer. Nonlinear regression methods estimated prevalent treatment costs for younger women with breast cancer compared with those without breast cancer. Individual medical costs were estimated by race/ethnicity and by type of services. Analyses were conducted in 2013 and all medical treatment costs were adjusted to 2012 U.S. dollars. RESULTS: The estimated monthly direct medical costs for breast cancer treatment among younger women enrolled in Medicaid was $5,711 (95% CI=$5,039, $6,383) per woman. The estimated monthly cost for outpatient services was $4,058 (95% CI=$3,575, $4,541), for inpatient services was $1,003 (95% CI=$708, $1,298), and for prescription drugs was $539 (95% CI=$431, $647). By race/ethnicity, non-Hispanic white women had the highest monthly total medical costs, followed by Hispanic women and non-Hispanic women of other race. CONCLUSIONS: Cost estimates demonstrate the substantial medical costs associated with breast cancer treatment for younger Medicaid beneficiaries. As the Medicaid program continues to evolve, the treatment cost estimates could serve as important inputs in decision making regarding planning for treatment of invasive breast cancer in this population. Published by Elsevier Inc.
INTRODUCTION: A few studies have examined the costs of breast cancer treatment in a Medicaid population at the state level. However, no study has estimated medical costs for breast cancer treatment at the national level for women aged 19-44 years enrolled in Medicaid. METHODS: A sample of 5,542 younger women aged 19-44 years enrolled in fee-for-service Medicaid with diagnosis codes for breast cancer in 2007 were compared with 4.3 million women aged 19-44 years enrolled in fee-for-service Medicaid without breast cancer. Nonlinear regression methods estimated prevalent treatment costs for younger women with breast cancer compared with those without breast cancer. Individual medical costs were estimated by race/ethnicity and by type of services. Analyses were conducted in 2013 and all medical treatment costs were adjusted to 2012 U.S. dollars. RESULTS: The estimated monthly direct medical costs for breast cancer treatment among younger women enrolled in Medicaid was $5,711 (95% CI=$5,039, $6,383) per woman. The estimated monthly cost for outpatient services was $4,058 (95% CI=$3,575, $4,541), for inpatient services was $1,003 (95% CI=$708, $1,298), and for prescription drugs was $539 (95% CI=$431, $647). By race/ethnicity, non-Hispanic white women had the highest monthly total medical costs, followed by Hispanic women and non-Hispanic women of other race. CONCLUSIONS: Cost estimates demonstrate the substantial medical costs associated with breast cancer treatment for younger Medicaid beneficiaries. As the Medicaid program continues to evolve, the treatment cost estimates could serve as important inputs in decision making regarding planning for treatment of invasive breast cancer in this population. Published by Elsevier Inc.
Authors: Theresa H M Keegan; Li Tao; Mindy C DeRouen; Xiao-Cheng Wu; Pinki Prasad; Charles F Lynch; Margarett Shnorhavorian; Brad J Zebrack; Roland Chu; Linda C Harlan; Ashley W Smith; Helen M Parsons Journal: J Cancer Surviv Date: 2014-01-10 Impact factor: 4.442
Authors: Cynthia D O'Malley; Sarah J Shema; Lisa S Clarke; Christina A Clarke; Carin I Perkins Journal: Am J Public Health Date: 2006-10-31 Impact factor: 9.308
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Justin G Trogdon; Donatus U Ekwueme; Diana Poehler; Cheryll C Thomas; Katherine Reeder-Hayes; Benjamin T Allaire Journal: Breast Cancer Res Treat Date: 2017-07-12 Impact factor: 4.872
Authors: Meredith L Shoemaker; Mary C White; Manxia Wu; Hannah K Weir; Isabelle Romieu Journal: Breast Cancer Res Treat Date: 2018-02-14 Impact factor: 4.872
Authors: Anagha Gogate; Stephanie B Wheeler; Katherine E Reeder-Hayes; Donatus U Ekwueme; Temeika L Fairley; Sarah Drier; Justin G Trogdon Journal: JNCI Cancer Spectr Date: 2021-07-13